Loading clinical trials...
Loading clinical trials...
The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of pos...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
First line of the email MUST contain NCT # and Site #.
CONTACT
Lead Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
NCT06191744 · Follicular Lymphoma (FL)
NCT07545603 · Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, and more
NCT06149286 · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
NCT06337318 · Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
CIBMTR
Milwaukee, Wisconsin
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions